Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00128232
Status:
COMPLETED
Last Update Posted:
2012-04-30
First Post:
2005-08-08
Brief Title:
Safety and Efficacy of Octreotide Long Acting Release LAR in Treatment Naïve Acromegalic Patients
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Safety and Efficacy of Octreotide LAR in Treatment Naïve Acromegalic Patients
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Currently the first line treatment for acromegaly is surgery in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly Octreotide LAR is approved for treatment of acromegaly after surgery if the disease is not controlled This study was aimed to test the safety and efficacy of octreotide LAR in acromegalic patients who did not have any previous treatment for acromegaly
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None